Abstract
The Human Genome Project provides insights so profound that it has the ability to change everything we know about medicine and how medicines are developed. Pharmacogenomics is defined as studies to identify the genes that are involved in determining the responsiveness to a given drug and to distinguish responders and non-responders to a given drug. Genome sequencing, transcriptome, and proteome analysis are of particular significance in pharmacogenomics. Transcriptome analysis can be done by methods of random cDNA sequencing, mRNA display and, differential hybridization (i.e., cDNA microarray and associated methods). Our results suggest that the pharmacogenomic transcriptome analysis and pharmainformatics have potential as strategies for defining novel drug targets in various diseases. Pharmacogenomics enhances the development, commercialization, and clinical use of conventional pharmaceutical products for common diseases, and it will eventually become a powerful tool for Evidence-Based Medicine. It is also important to predict interindividual pharmacokinetic differences by genetic polymorphisms of transporters or pharmacokinetic changes by transporter-mediated drug interactions during drug development. Pharmacogenomics and pharmainformatics enable us to move quickly and efficiently from targets to appropriate medicines.
